Form 4: Sensei Biotherapeutics CEO Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Sensei Biotherapeutics President and PEO Christopher Gerry was granted 220,000 stock options following shareholder approval of the 2026 Equity Incentive Plan.
Summary
- Christopher Gerry, President and PEO of Sensei Biotherapeutics, Inc., received a grant of 220,000 stock options.
- The grant was initially approved by the Board on April 10, 2026, and finalized following shareholder approval of the 2026 Equity Incentive Plan on June 10, 2026.
- The options have an exercise price of $29.89 per share.
- The options vest over a four-year period, with 25% vesting on April 10, 2027, and the remainder in 36 equal monthly installments.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
- Successful shareholder approval of the 2026 Equity Incentive Plan.
Negatives
- Potential for future shareholder dilution upon the exercise of the granted stock options.
Risks
- Vesting is contingent upon the Reporting Person's continuous service with the Issuer.
- Market price volatility may impact the future value of the granted options.
Future Outlook
The filing does not provide specific forward-looking financial guidance, focusing instead on executive compensation structure.
Industry Context
StockSavvy.ai notes that equity grants for executive leadership are standard practice in the biotechnology sector to incentivize long-term retention and performance, particularly following the adoption of new incentive plans.
Comparison to Industry Standards
- The four-year vesting schedule with a one-year cliff is consistent with standard industry practices for executive equity compensation.
- The use of the closing price on the date of Board approval for the exercise price is a common governance practice to ensure fair market value pricing.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Adoption | Shareholders approved the 2026 Equity Incentive Plan. | 06/10/2026 | Provides the framework for future equity-based compensation for employees and executives. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of the first tranche of options on April 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/10/2026 | Date of Board approval for the stock option grant and determination of exercise price. |
| 06/10/2026 | Date of shareholder approval of the 2026 Equity Incentive Plan and grant date. |
| 04/10/2027 | Initial vesting date for 25% of the granted options. |
| 04/10/2030 | Full vesting date for the option grant. |
| 06/09/2036 | Expiration date of the stock options. |
Keywords
Sensei Biotherapeutics, SNSE, Form 4, Executive Compensation, Stock Options, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.